These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8547684)

  • 1. Disinfectant drugs regulation.
    Perron N; Carman M
    Can J Infect Control; 1995; 10(4):117-8. PubMed ID: 8547684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 3. The pediatric research equity act and oncology.
    Hirschfeld S
    Pediatr Blood Cancer; 2004 Aug; 43(2):99-102. PubMed ID: 15236272
    [No Abstract]   [Full Text] [Related]  

  • 4. Legislative and regulatory modernization for therapeutic products.
    Maher M
    J Popul Ther Clin Pharmacol; 2010; 17(3):e341-8. PubMed ID: 21041867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emergency Drug Release Program: regulatory aspects of new drug access in Canada.
    Gilron I
    CMAJ; 1993 Apr; 148(7):1151-3. PubMed ID: 8457955
    [No Abstract]   [Full Text] [Related]  

  • 6. [Status of drugs].
    Gindre I; Woronoff-Lemsi MC
    Soins; 1998 Nov; (630):57-8. PubMed ID: 10095734
    [No Abstract]   [Full Text] [Related]  

  • 7. John Jenkins.
    Nat Rev Drug Discov; 2017 Feb; 16(2):80. PubMed ID: 28148942
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulating new psychoactive drugs: innovation leading to compromise.
    Schep LJ; Gee P; Tingle M; Galea S; Newcombe D
    BMJ; 2014 Aug; 349():g5085. PubMed ID: 25122194
    [No Abstract]   [Full Text] [Related]  

  • 9. The new FDA pregnancy labeling requirements for drugs.
    Frederiksen MC
    J Midwifery Womens Health; 2011; 56(3):303-7. PubMed ID: 21535377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Governance of natural health products regulation: an iterative process.
    Walji R; Wiktorowicz M
    Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks.
    Bloem LT; Karomi M; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Mantel-Teeuwisse AK
    Expert Opin Drug Saf; 2021 Nov; 20(11):1433-1442. PubMed ID: 34263667
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulations and procedures for new drug evaluation and approval in China.
    Yin H
    Hum Gene Ther; 2006 Oct; 17(10):970-4. PubMed ID: 16958562
    [No Abstract]   [Full Text] [Related]  

  • 13. Official evaluation of disinfectants in the Netherlands.
    van Klingeren B; Mossel DA
    Zentralbl Bakteriol Orig B; 1978 Jun; 166(6):540-1. PubMed ID: 696070
    [No Abstract]   [Full Text] [Related]  

  • 14. Company ordered to halt sales of unapproved drugs, reimburse buyers.
    FDA Consum; 2004; 38(5):5. PubMed ID: 15595134
    [No Abstract]   [Full Text] [Related]  

  • 15. Crackdown on factory farm drug use urged.
    Webster PC
    CMAJ; 2012 Jan; 184(1):E23-4. PubMed ID: 22125329
    [No Abstract]   [Full Text] [Related]  

  • 16. [Generics: authorization to market and quality guarantees].
    De Muylder JA
    Rev Med Brux; 2000 Sep; 21(4):A276-8. PubMed ID: 11068480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appraisal of the narcotic drugs and psychotropic substances (amendment) act, 2014.
    Mohapatra S; Rath N
    Asian J Psychiatr; 2015 Apr; 14():80-1. PubMed ID: 25838083
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.
    Shah RR
    Fundam Clin Pharmacol; 2002 Apr; 16(2):147-56. PubMed ID: 12031067
    [No Abstract]   [Full Text] [Related]  

  • 19. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Readers' responses to "it is time for marijuana to be reclassified as something other than a schedule I drug".
    Verhaagh DJ
    MedGenMed; 2005; 7(4):35; author reply 34. PubMed ID: 16671172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.